| Menorrhagia
Natazia vs Oriahnn
Side-by-side clinical, coverage, and cost comparison for menorrhagia.Deep comparison between: Natazia vs Oriahnn with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsOriahnn has a higher rate of injection site reactions vs Natazia based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Oriahnn but not Natazia, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Natazia
Oriahnn
At A Glance
Oral
Daily
Combined oral contraceptive
Oral
Twice daily
GnRH receptor antagonist
Indications
- Menorrhagia
- Menorrhagia
- Uterine Fibroids
Dosing
Menorrhagia One tablet daily by mouth at the same time every day, taken in the order directed on the blister pack for a 28-day sequential regimen; do not skip or delay intake by more than 12 hours.
Menorrhagia, Uterine Fibroids One elagolix 300 mg/estradiol 1 mg/norethindrone acetate 0.5 mg capsule orally in the morning and one elagolix 300 mg capsule orally in the evening, for up to 24 months.
Contraindications
- Smoking if over age 35
- Deep vein thrombosis or pulmonary embolism, current or past
- Cerebrovascular disease
- Coronary artery disease
- Thrombogenic valvular or thrombogenic rhythm diseases of the heart (e.g., subacute bacterial endocarditis with valvular disease, or atrial fibrillation)
- Inherited or acquired hypercoagulopathies
- Uncontrolled hypertension
- Diabetes mellitus with vascular disease
- Headaches with focal neurological symptoms, or migraine headaches with or without aura if over age 35
- Undiagnosed abnormal uterine bleeding
- Current or history of breast cancer which may be hormone sensitive
- Liver tumors (benign or malignant) or liver disease
- High risk of arterial, venous thrombotic, or thromboembolic disorders (including women over 35 who smoke and those with history of DVT, pulmonary embolism, vascular disease, thrombogenic cardiac conditions, hypercoagulopathies, uncontrolled hypertension, or migraine with aura over age 35)
- Pregnancy
- Known osteoporosis
- Current or history of breast cancer or other hormonally-sensitive malignancies, or increased risk for hormonally-sensitive malignancies
- Known hepatic impairment or disease
- Undiagnosed abnormal uterine bleeding
- Known anaphylactic reaction, angioedema, or hypersensitivity to ORIAHNN or any of its components
- Concomitant use of OATP1B1 inhibitors known or expected to significantly increase elagolix plasma concentrations
Adverse Reactions
Most common (>=2%) Headache (including migraines), breast pain or tenderness, menstrual disorders, nausea or vomiting, acne, mood changes, increased weight
Serious Myocardial infarction, ruptured ovarian cyst, deep vein thrombosis, focal nodular hyperplasia of the liver, uterine leiomyoma, acute cholecystitis, chronic acalculous cholecystitis
Postmarketing Venous and arterial thromboembolic events, hypertension, gallbladder disease, hepatitis, hypersensitivity, fluid retention, hypertriglyceridemia, dizziness, chloasma, angioedema, erythema nodosum, erythema multiforme, gastrointestinal symptoms, vulvovaginal candidiasis
Most common (>=5%) Hot flush, headache, fatigue, metrorrhagia
Serious Thromboembolic and vascular events, bone loss, suicidal ideation and behavior, exacerbation of mood disorders, hepatic transaminase elevations, elevated blood pressure, alopecia, changes in lipid parameters
Pharmacology
Combined oral contraceptive (COC) that lowers the risk of pregnancy primarily by suppressing ovulation; contains estradiol valerate, a synthetic prodrug of 17beta-estradiol, and dienogest, a progestin with properties of both 19-nortestosterone and progesterone derivatives.
GnRH receptor antagonist combination; elagolix competitively binds GnRH receptors in the pituitary gland, suppressing LH and FSH and reducing ovarian estradiol and progesterone, with add-back estradiol/norethindrone acetate to mitigate bone loss and protect the endometrium from unopposed estrogen effects.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Natazia
- Covered on 5 commercial plans
- PA (2/12) · Step Therapy (0/12) · Qty limit (0/12)
Oriahnn
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (1/12) · Qty limit (9/12)
UnitedHealthcare
Natazia
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Oriahnn
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (5/8)
Humana
Natazia
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Oriahnn
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Natazia.
$0
myAbbVie Assist: Women's HealthCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NataziaView full Natazia profile
OriahnnView full Oriahnn profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.